Official PayPal Seal

Fully-Invested? Why? Thoughts on Microsoft and Eli Lilly, and Celgene

publication date: Jan 3, 2019
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Our methodology is really easy to understand once you get to know the things we’re looking at. There’s also some subjectivity in how we implement our thoughts in the simulated newsletter portfolios, and please stop calling what we do advice. We’re a financial publisher. While we’re at it, let’s talk a bit about Microsoft, Eli Lilly, and Celgene through the lens of our methodology.

Subscribe Now to Gain Access!

This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!

Click to Learn More about Valuentum

If you are already a subscriber, please

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.

To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.